about
Hypoglycemia in Patients with Diabetes and Renal DiseaseSodium-Glucose linked transporter 2 (SGLT2) inhibitors--fighting diabetes from a new perspective.The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.Angiotensin receptor blocker telmisartan suppresses renal gluconeogenesis during starvationPharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.Critical Roles of Two Hydrophobic Residues within Human Glucose Transporter 9 (hSLC2A9) in Substrate Selectivity and Urate Transport.Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study.Sodium-glucose cotransport.Antidiabetic agents: past, present and future.Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.Distribution of glucose transporters in renal diseases.Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.Characterization of the transport activity of SGLT2/MAP17, the renal low-affinity Na+-glucose cotransporter.
P2860
Q26799515-96D44FBB-B205-4FA1-9C5C-A1654085361DQ30833760-EA872E83-975A-4B25-B948-BBCB2D2C91C4Q34503796-96F97BCE-CDB5-4F7F-8542-C1E26737BD48Q35105160-3ACD02D4-3F11-4728-B5DE-90BDF445D2AEQ35558413-75E4AB68-E017-4257-A66C-B1B2282E9D56Q35721909-F1850CCA-3762-460D-B433-082826163818Q36179371-AE7A409C-B824-4D05-A864-0B6E5EF88B0BQ36851156-FA665D4B-D916-4D91-90CE-983FAF6DDC51Q37559899-D2128931-4B0D-492E-9DE1-BFE455D8D04AQ37718851-FACFF106-48AD-48C8-BB2B-B05B6302F14FQ38089737-48F9A123-EB6F-4459-8A39-E60C1C4DA7F7Q38130748-44CC46E0-F9A9-4669-95FD-0FB2BB9F6AE9Q38715153-C4087257-98CB-43F1-AD11-BA2B9A27C3E7Q38961637-2075CD74-3F10-41B7-A221-04619A03C1DEQ39170860-7914918B-2AD8-4F65-B450-592BE677E16DQ39255188-1319E5F8-BAFF-4750-8581-D079A941C6A1Q41570521-3D10636A-D770-4C78-9847-CC518B9E49D9Q42388524-BB0A076E-CF6D-4B83-89A5-1799A5E0A09CQ46320593-D5E2EF81-CFD2-49DB-8B6A-9E2D86715034Q48519713-A576F3F4-C0E9-4F7E-8986-CB4B2B301B8B
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Sodium glucose cotransporter 2 and the diabetic kidney.
@en
type
label
Sodium glucose cotransporter 2 and the diabetic kidney.
@en
prefLabel
Sodium glucose cotransporter 2 and the diabetic kidney.
@en
P2093
P1476
Sodium glucose cotransporter 2 and the diabetic kidney.
@en
P2093
Amanda Mather
Carol Pollock
Muralikrishna Gangadharan Komala
Usha Panchapakesan
P304
P356
10.1097/MNH.0B013E32835A17AE
P577
2013-01-01T00:00:00Z